Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $7.2652W HIGH $16.38
Volume
4.24 M
Value Traded
88.04 M
Short % Float
7.84%
-0.89%Week
+5.31%1 Month
+48.39%3 Month
+91.56%6 Month
-74.15%5 Year
-44.84%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
10.60 B
EPS (TTM)
-0.85
P/E Ratio
-
Ent. Value
14.03 B
Total Shares
676.36 M
Float Shares
655.59 M
Insiders
3.07%
Institutions
102.35%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
AVTR Catalyst Timeline
Dated clinical, regulatory and corporate events for Avantor, Inc.
Past FDA Catalysts and PDUFA Decisions
How AVTR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Avantor, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every AVTR program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| LUCIER GREGORY TDirector | Buy | 10,000 60,000 held | $8.32 | 05/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AVTR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PROSIGHT MANAGEMENT, LP | 2.1 % (61.5 %) | 10.30 M | 898.50 K | 632.46% ( 775.83 K) |
AVTR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AVTR ranks across every disease it competes in
Competitive Position is a premium feature
See how AVTR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAVTR News
AVTRAvantor® to Report Third Quarter 2026 Earnings on Wednesday, October 28, 2026
Avantor, Inc. will announce its third quarter 2026 financial results on October 28, 2026, before market opening. A conference call will follow at 8:00 a.m. Eastern Time. The company is recognized for its critical products and services in life sciences and advanced technology, serving over 300,000 customers globally.
Read more →AVTRAvantor appoints new Chief Financial Officer
Avantor, Inc. has appointed Todd Garner as the new Chief Financial Officer, effective September 21, 2026. Garner, who has over 30 years of financial leadership experience, will oversee the company's global finance organization. CEO Emmanuel Ligner expressed confidence in Garner's ability to drive growth and create value as Avantor continues to serve its customers worldwide.
Read more →AVTR▲ +15.8%on this news
Avantor® Reports Second Quarter 2026 Results
Avantor, Inc. reported its second quarter 2026 results, showing a slight increase in net sales to $1,692.3 million, despite a 0.4% organic decline. The company generated a free cash flow of $142.8 million, which was used to repay $112.1 million in debt. Although net income decreased significantly, Avantor raised its fiscal 2026 guidance for organic revenue growth and adjusted EPS, reflecting improved business performance.
Read more →AVTR▲ +6.9%on this news
Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product
Avantor's NuSil brand has expanded its partnership with the Population Council to develop a three-month dapivirine vaginal ring for HIV prevention. This new product aims to improve adherence and convenience, requiring only four rings per year. The collaboration highlights Avantor's commitment to innovative healthcare solutions, although the product is still under regulatory review.
Read more →AVTRCell Culture Media Market worth $12.9 billion by 2033: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG
The global cell culture media market is expected to grow from $5.3 billion in 2026 to $12.9 billion by 2033, driven by the increasing demand for biologics and cell therapies. Key factors include the shift towards serum-free and chemically defined media, which enhance production efficiency and regulatory compliance. North America leads the market, while Asia Pacific shows the fastest growth potential.
Read more →AVTRAvantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026
Avantor, Inc. has announced that it will release its second quarter 2026 financial results on July 29, 2026, before the market opens. A conference call will follow at 8:00 a.m. EDT to discuss these results. The company emphasizes its role in supporting critical research and development activities globally.
Read more →AVTRAvantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
Avantor, Inc. has appointed Gerard (Jerry) Porreca as Executive Vice President of Quality and Regulatory. He will oversee quality assurance and regulatory affairs globally. Porreca has significant experience in the life sciences and healthcare sectors, previously leading quality initiatives at Getinge and other companies. His expertise is expected to enhance Avantor's operations and customer solutions.
Read more →AVTRAvantor Reports First Quarter 2026 Results
Avantor, Inc. reported its first-quarter 2026 financial results, highlighting net sales of $1,581 million and a net income of $43 million. The results indicated that the performance exceeded expectations, particularly in the Bioscience and Medtech product areas. However, the company noted a decline in organic net sales primarily due to foreign currency adjustments. Despite a decrease in net income compared to the previous year, Avantor reaffirmed its fiscal 2026 guidance, suggesting confidence in its operational stability.
Read more →AVTR▼ -6.3%on this news
Avantor® Announces Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer
Avantor, Inc. has appointed Ludovic Brellier as Executive Vice President for Bioscience & Medtech Products and Chief Transformation Officer, effective May 1, 2026. Brellier, who previously led business units at Cytiva, will focus on enhancing operational performance and driving transformation initiatives. His leadership is expected to unlock growth potential within Avantor's BMP segment.
Read more →AVTRAvantor® Enhances U.S. Biomanufacturing Infrastructure with Expanded Stability and Microbial Testing Facility
Avantor, Inc. has announced the expansion of its St. Louis manufacturing site to include advanced microbial and stability testing. This enhancement aims to strengthen U.S. biopharma manufacturing support and improve supply chain efficiency. The facility is designed to meet global regulatory standards, ensuring high-quality service and faster product development timelines.
Read more →AVTRAvantor® to Report First Quarter 2026 Earnings on Wednesday, April 29, 2026
Avantor, Inc. has announced the release date for its first quarter 2026 earnings report, which will occur before the market opens on April 29, 2026. Following the release, a conference call will be held at 8:00 a.m. EDT to discuss the results. Investors can access the live audio webcast on Avantor's website.
Read more →AVTRAvantor® Announces CFO Transition
Avantor, Inc. has announced the upcoming departure of CFO R. Brent Jones, effective on or before June 24, 2026. To ensure continuity, Steve Eck, the current Senior Vice President and Chief Accounting Officer, will take over as interim CFO. The company has also reaffirmed its financial guidance for 2026.
Read more →AVTR▼ -13.6%on this news
Avantor® Reports Fourth Quarter and Full Year 2025 Results
Avantor, Inc. reported its financial results for Q4 and the full year 2025, revealing a decrease in net sales and a significant net loss. The company is implementing a Revival program aimed at improving its operational agility and market competitiveness. Despite the challenges, Avantor's leadership expresses confidence in their strategic initiatives for future growth.
Read more →AVTRAvantor® to Participate in 44th Annual J.P. Morgan Healthcare Conference
Avantor, Inc. announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, where CEO Emmanuel Ligner will present on January 14, 2026. The event is significant for showcasing advancements in life sciences and technology. A live audio webcast will be available, with a replay accessible for 30 days.
Read more →AVTR▼ -23.2%on this news
Avantor Reports Third Quarter 2025 Results
Avantor, Inc. reported a net loss of $712 million for the third quarter of 2025, significantly down from a net gain of $57.8 million the previous year. The company experienced a 5% decrease in net sales to $1.62 billion, including a major non-cash goodwill impairment charge. Despite these challenges, Avantor announced a $500 million share repurchase program and reported an adjusted EBITDA of $268 million, reflecting ongoing operational activity. The management is implementing changes to its strategies to enhance performance and shareholder value.
Read more →AVTR▼ -15.5%on this news
Avantor Reports Second Quarter 2025 Results
Avantor, Inc. reported its second quarter 2025 financial results, revealing net sales of $1.68 billion, a 1% decrease from the previous year. Net income fell to $65 million, down from $92.9 million a year ago, while adjusted EBITDA stood at $280 million. The company saw revenue growth in its Laboratory Solutions segment and secured major contracts, although performance was impacted by planned maintenance and regulatory challenges in the Bioscience Production segment. Changes in leadership were also announced, with new CEO Emmanuel Ligner set to take over in August 2025.
Read more →AVTR▼ -7.1%on this news
Avantor Announces Emmanuel Ligner as Next President and CEO Seasoned Executive with Proven Track Record of Value Creation in Life Sciences
Avantor, Inc. has announced the appointment of Emmanuel Ligner as its new President and CEO, effective August 18, 2025. Ligner, who has over 30 years of experience in the life sciences sector, succeeds Michael Stubblefield. He previously led Cytiva and held a significant role at GE Life Sciences, indicating a strong background in driving growth and leadership. The Board expressed confidence that Ligner will guide Avantor towards achieving its strategic objectives in Lab Solutions and Bioscience Production.
Read more →AVTR▼ -16.6%on this news
Avantor Reports First Quarter 2025 Results
Avantor, Inc. reported its financial results for the first quarter of 2025, revealing a net sales decline of 6% year-over-year, totaling $1.58 billion. Despite an increase in net income to $64.5 million, the company's performance was affected by decreased demand in the Education and Government sectors. In response, Avantor is implementing strategic actions to enhance its cost structure, targeting $400 million in gross run-rate savings by the end of 2027. The company remains confident in its long-term value creation potential, even amidst challenging market conditions.
Read more →About Avantor, Inc.
HeadquartersRADNOR CORPORATE CENTER, BUILDING ONE, RADNOR, PA, 19087
BIOPHARMAWATCH ELITE PLUS
Trade the next AVTR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime